These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39194584)

  • 1. Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center.
    Barlas T; Sutcuoglu O; Akdogan O; Balos Toruner F; Akturk M; Ozdemir N; Yazici O; Eroglu Altinova A
    Endocr Relat Cancer; 2024 Nov; 31(11):. PubMed ID: 39194584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma.
    Miura Y; Motoshima T; Anami T; Yano H; Mito R; Pan C; Urakami S; Kinowaki K; Tsukamoto H; Kurahashi R; Murakami Y; Yatsuda J; Fujiwara Y; Kamba T; Komohara Y
    Microbiol Immunol; 2023 Jul; 67(7):345-354. PubMed ID: 36975091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors-Induced Endocrinopathies: Assessment, Management and Monitoring in a Comprehensive Cancer Centre.
    Elshafie O; Khalil AB; Salman B; Atabani A; Al-Sayegh H
    Endocrinol Diabetes Metab; 2024 Jul; 7(4):e00505. PubMed ID: 38932429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival.
    Yang L; Murthy S; Cortellini A; Lim EA; Gonzalez M; Pinato DJ; Abdel-Malek M; Mahmoud S; Martin NM
    Front Endocrinol (Lausanne); 2024; 15():1369268. PubMed ID: 38681767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
    Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
    Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
    Iwama S; Kobayashi T; Arima H
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 10. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
    Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
    Front Immunol; 2022; 13():987568. PubMed ID: 36159840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy.
    Luongo C; Morra R; Gambale C; Porcelli T; Sessa F; Matano E; Damiano V; Klain M; Schlumberger M; Salvatore D
    J Endocrinol Invest; 2021 Sep; 44(9):1927-1933. PubMed ID: 33576954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
    Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
    Front Immunol; 2022; 13():779691. PubMed ID: 35558065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine immune-related adverse effects of immune-checkpoint inhibitors.
    Trevisani V; Iughetti L; Lucaccioni L; Predieri B
    Expert Rev Endocrinol Metab; 2023; 18(5):441-451. PubMed ID: 37682107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.
    Borgers JSW; van Wesemael TJ; Gelderman KA; Rispens T; Verdegaal EME; Moes DJAR; Korse CM; Kapiteijn E; Welters MJP; van der Burg SH; van Houdt WJ; van Thienen JV; Haanen JBAG; van der Woude D
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38945553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The association between baseline TPOAb and/or TgAb positivity and thyroid immune-related adverse events in patients with malignancies following treatment with immune checkpoint inhibitors].
    Gao Y; Ye T; Wu LG; Xu Y; Wang X; Cheng XQ; Zhang YL; Wang YY; Fan XR; Zhao HT; Liu H; Chai XF; Zhang L; Wang MZ; Li NS; Lian XL
    Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(12):963-969. PubMed ID: 38514346
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.